Glucose-insulin-potassium solution protects ventricular myocytes of neonatal rat in an in vitro coverslip ischemia/reperfusion model

Korean Circulation Journal

Volumn 45, Issue 3, 2015, Pages 234-241

  Chun, Woo Jung ^a   Nah, Deuk Young ^b   Bae, Jun Ho ^b   Chung, Jin Wook ^b   Lee, HyunSook ^c   Moon, Il Soo ^c  

^a Sungkyunkwan University   (South Korea)

^b Dongguk University   (South Korea)

^c Dongguk University College of Medicine   (South Korea)

Author keywords

GlcNac; Glucose insulin potassium cardioplegic solution; Myocytes, cardiac; O GlcNAc transferase

Indexed keywords

CARDIOPLEGIC AGENT; GLUCOSE; INSULIN; N ACETYLGLUCOSAMINE; N ACETYLGLUCOSAMINE TRANSFERASE; POTASSIUM; REACTIVE OXYGEN METABOLITE; TRANSFERASE; UNCLASSIFIED DRUG;

ACYLATION; ANIMAL CELL; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CELL PROTECTION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; EXPERIMENTAL MODEL; HEART CELL CULTURE; HEART MUSCLE CELL; HEART MUSCLE NECROSIS; HEART PROTECTION; IN VITRO STUDY; NEWBORN; NONHUMAN; OXIDATIVE STRESS; PHASE CONTRAST MICROSCOPY; PROTEIN EXPRESSION; RAT; REPERFUSION INJURY;

EID: 84930411051     PISSN: 17385520     EISSN: 17385555     Source Type: Journal    
DOI: 10.4070/kcj.2015.45.3.234     Document Type: Article

References (30)

1. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007;357:1121-35.
2. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986;74:1124-36.
3. Thibault H, Angoulvant D, Bergerot C, Ovize M. Postconditioning the human heart. Heart Metab 2007;37:19-22.
4. Jovic M, Gradinac S, Lausevic-Vuk L, et al. Preconditioning with glucoseinsulin-potassium solution and restoration of myocardial function during coronary surgery. Gen Physiol Biophys 2009;28:262-70.
5. Sodi-Pallares D, Testelli MR, Fishleder BL, et al. Effects of an intravenous infusion of a potassium-glucose-insulin solution on the electrocardiographic signs of myocardial infarction. A preliminary clinical report. Am J Cardiol 1962;9:166-81.
6. Apstein CS, Taegtmeyer H. Glucose-insulin-potassium in acute myocardial infarction: the time has come for a large, prospective trial. Circulation 1997;96:1074-7.
7. Oliver EMF, Opie LH. Effects of glucose and fatty acids on myocardial ischemia and arrhythmias. Lancet 1994;343:155-8.
8. Obeid AI, Varrier RL, Lown B. Influence of glucose, insulin, and potassium on vulnerability to ventricular fibrillation in the canine heart. Circ Res 1978;43:601-8.
9. Cave AC, Ingwall JS, Friedrich J, Liao R, Saupe KW, Apstein CS, Eberli FR. ATP synthesis during low-flow ischemia: influence of increased glycolytic substrate. Circulation 2000;101:2090-6.
10. Brown MJ, Brown DC, Murphy MB. Hypokalemia from beta2-receptor stimulation by circulating epinephrine. N Engl J Med 1983;309:1414-9.
11. Oliver MF, Kurien VA, Greenwood TW. Relation between serum-freefatty acids and arrhythmias and death after acute myocardial infarction. Lancet 1968;1:710-4.
12. Ji L, Fu F, Zhang L, et al. Insulin attenuates myocardial ischemia/reperfusion injury via reducing oxidative/nitrative stress. Am J Physiol Endocrinol Metab 2010;298:E871-80.
13. Krljanac G, Vasiljević Z, Radovanović. M, et al. Effects of glucose-insulinpotassium infusion on ST-elevation myocardial infarction in patients treated with thrombolytic therapy. Am J Cardiol 2005;96:1053-8.
14. Yusuf S, Mehta SR, Diaz R, et al. Challenges in the conduct of large simple trials of important generic questions in resource-poor settings: the CREATE and ECLA trial program evaluating GIK (glucose, insulin and potassium) and low-molecular-weight heparin in acute myocardial infarction. Am Heart J 2004;148:1068-78.
15. Mehta SR, Yusuf S, Diaz R, et al. Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. JAMA 2005;293:437-46.
16. Rasoul S, Ottervanger JP, Timmer JR, et al. One year outcomes after glucose-insulin-potassium in ST elevation myocardial infarction. The Glucose-insulin-potassium study II. Int J Cardiol 2007;122:52-5.
17. Diaz R, Goyal A, Mehta SR, et al. Glucose-insulin-potassium therapy in patients with ST-segment elevation myocardial infarction. JAMA 2007;298:2399-405.
18. Hart GW, Kreppel LK, Comer FI, et al. O-GlcNAcylation of key nuclear and cytoskeletal proteins: reciprocity with O-phosphorylation and putative roles in protein multimerization. Glycobiology 1996;6:711-6.
19. Zachara NE, O'Donnell N, Cheung WD, Mercer JJ, Marth JD, Hart GW. Dynamic O-GlcNAc modification of nucleocytoplasmic proteins in response to stress. A survival response of mammalian cells. J Biol Chem 2004;279:30133-42.
20. Howell NJ, Ashrafian H, Drury NE, et al. Glucose-insulin-potassium reduces the incidence of low cardiac output episodes after aortic valve replacement for aortic stenosis in patients with left ventricular hypertrophy: results from the Hypertrophy, Insulin, Glucose and Electrolytes (HINGE) trial. Circulation 2011;123:170-7.
21. Pitts KR, Toombs CF. Coverslip hypoxia: a novel method for studying cardiac myocyte hypoxia and ischemia in vitro. Am J Physiol Heart Circ Physiol 2004;287:H1801-12.
22. Rohr S, Scholly DM, Kleber AG. Patterned growth of neonatal rat heart cells in culture. Morphological and electrophysiological characterization. Circ Res 1991;68:114-30.
23. Moon IS, Cho SJ, Jin I, Walikonis R. A simple method for combined fluorescence in situ hybridization and immunocytochemistry. Mol Cells 2007;24:76-82.
24. Grossman AN, Opie LH, Beshansky JR, Ingwall JS, Rackley CE, Selker HP. Glucose-insulin-potassium revived: current status in acute coronary syndromes and the energy-depleted heart. Circulation 2013;127:1040-8.
25. Carbo R, Nava P, Guarner V. Effects of polarizing solution on glucose uptake of rat oxygenated or hypoxic ventricular myocytes. Clin Exp Pharmacol Physiol 2003;30:64-71.
26. Laybutt DR, Thompson AL, Cooney GJ, Kraegen EW. Selective chronic regulation of GLUT1 and GLUT4 content by insulin, glucose and lipid in rat cardiac muscle in vivo. Am J Physiol 1997;273:H1309-16.
27. Darley-Usmar VM, Ball LE, Chatham JC. Protein O-linked β-Nacetylglucosamine: a novel effector of cardiomyocyte metabolism and function. J Mol Cell Cardiol 2012;52:538-49.
28. Champattanachai V, Marchase RB, Chatham JC. Glucosamine protects neonatal cardiomyocytes from ischemia-reperfusion injury via increased protein-associated O-GlcNAc. Am J Physiol Cell Physiol 2007;292:C178-87.
29. Ngoh GA, Watson LJ, Facundo HT, Dillmann W, Jones SP. Non-canonical glycosyltransferase modulates post-hypoxic cardiac myocyte death and mitochondrial permeability transition. J Mol Cell Cardiol 2008;45:313-25.
30. Ngoh GA, Facundo HT, Hamid T, Dillmann W, Zachara NE, Jones SP. Unique hexosaminidase reduces metabolic survival signal and sensitizes cardiac myocytes to hypoxia/reoxygenation injury. Circ Res 2009;104:41-9.